Study · Not a test of the peptide alone · 2012

12 results

Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.

Davies MJ, Chubb BD, Smith IC, Valentine WJ

Diabetic medicine : a journal of the British Diabetic Association1 Mar 2012Cited by 37 (Europe PMC)

PMID21883438PMCIDPMC3378710DOI10.1111/j.1464-5491.2011.03429.xPepBankPUB-21883438

Summary

AimTo investigate the cost-effectiveness of liraglutide as add-on to metformin vs. glimepiride or sitagliptin in patients with Type 2 diabetes uncontrolled with first-line metformin.MethodsData were sourced from a clinical trial comparing liraglutide vs. glimepiride, both in combination with metformin, and a clinical trial comparing liraglutide vs. sitagliptin, both as add-on to metformin. Only the subgroup of patients in whom liraglutide was added to metformin monotherapy was included in the cost-utility analysis. The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes. Treatment effects were taken directly from the trials. Costs and outcomes were discounted at 3.5% per annum and costs were accounted from a third-party payer (UK National Health System) perspective.ResultsTreatment with liraglutide 1.2 and 1.8 mg resulted, respectively, in mean increases in quality-adjusted life expectancy of 0.32 ± 0.15 and 0.28 ± 0.14 quality-adjusted life years vs. glimepiride, and 0.19 ± 0.15 and 0.31 ± 0.15 quality-adjusted life years vs. sitagliptin, and was associated with higher costs of £ 3003 ± £ 678 and £ 4688 ± £ 639 vs. glimepiride, and £ 1842 ± £ 751 and £ 3224 ± £ 683 vs. sitagliptin, over a patient's lifetime. Both liraglutide doses were cost-effective, with incremental cost-effectiveness ratios of £ 9449 and £ 16,501 per quality-adjusted life year gained vs. glimepiride, and £ 9851 and £ 10,465 per quality-adjusted life year gained vs. sitagliptin, respectively.ConclusionsLiraglutide, added to metformin monotherapy, is a cost-effective option for the treatment of Type 2 diabetes in a UK setting.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.2 mg gave a mean gain of 0.32 quality-adjusted life years versus glimepiride.
In plain wordsIn a computer model, liraglutide 1.2 mg added 0.32 quality-adjusted life years compared with glimepiride.
Peptide
Liraglutide
Outcome
IncreaseGain in quality-adjusted life expectancy, liraglutide 1.2 mg versus glimepiride
Study
n: not reported in source
CORE Diabetes Model
Comparator
Glimepiride
Outcome group
Cost-effectiveness · Whole body
Measurements
QALE gain
0.32 QALY
liraglutide 1.2 mg vs glimepiride
Source sentences
Summary
mean increases in quality-adjusted life expectancy of 0.32 ± 0.15 and 0.28 ± 0.14 quality-adjusted life years vs. glimepiride
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343801
02Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.8 mg gave a mean gain of 0.28 quality-adjusted life years versus glimepiride.
In plain wordsIn a computer model, liraglutide 1.8 mg added 0.28 quality-adjusted life years compared with glimepiride.
Peptide
Liraglutide
Outcome
IncreaseGain in quality-adjusted life expectancy, liraglutide 1.8 mg versus glimepiride
Study
n: not reported in source
CORE Diabetes Model
Comparator
Glimepiride
Outcome group
Cost-effectiveness · Whole body
Measurements
QALE gain
0.28 QALY
liraglutide 1.8 mg vs glimepiride
Source sentences
Summary
mean increases in quality-adjusted life expectancy of 0.32 ± 0.15 and 0.28 ± 0.14 quality-adjusted life years vs. glimepiride
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343802
03Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.2 mg gave a mean gain of 0.19 quality-adjusted life years versus sitagliptin.
In plain wordsIn a computer model, liraglutide 1.2 mg added 0.19 quality-adjusted life years compared with sitagliptin.
Peptide
Liraglutide
Outcome
IncreaseGain in quality-adjusted life expectancy, liraglutide 1.2 mg versus sitagliptin
Study
n: not reported in source
CORE Diabetes Model
Comparator
Sitagliptin
Outcome group
Cost-effectiveness · Whole body
Measurements
QALE gain
0.19 QALY
liraglutide 1.2 mg vs sitagliptin
Source sentences
Summary
0.19 ± 0.15 and 0.31 ± 0.15 quality-adjusted life years vs. sitagliptin
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343803
04Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.8 mg gave a mean gain of 0.31 quality-adjusted life years versus sitagliptin.
In plain wordsIn a computer model, liraglutide 1.8 mg added 0.31 quality-adjusted life years compared with sitagliptin.
Peptide
Liraglutide
Outcome
IncreaseGain in quality-adjusted life expectancy, liraglutide 1.8 mg versus sitagliptin
Study
n: not reported in source
CORE Diabetes Model
Comparator
Sitagliptin
Outcome group
Cost-effectiveness · Whole body
Measurements
QALE gain
0.31 QALY
liraglutide 1.8 mg vs sitagliptin
Source sentences
Summary
0.19 ± 0.15 and 0.31 ± 0.15 quality-adjusted life years vs. sitagliptin
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343804
05Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.2 mg raised lifetime costs by £3003 versus glimepiride.
In plain wordsIn a computer model, liraglutide 1.2 mg cost £3003 more over a lifetime than glimepiride.
Peptide
Liraglutide
Outcome
IncreaseLifetime cost, liraglutide 1.2 mg versus glimepiride
Study
n: not reported in source
CORE Diabetes Model
Comparator
Glimepiride
Outcome group
Cost-effectiveness · Whole body
Measurements
Incremental cost
3003 £
liraglutide 1.2 mg vs glimepiride
Source sentences
Summary
higher costs of £ 3003 ± £ 678 and £ 4688 ± £ 639 vs. glimepiride
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343805
06Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.8 mg raised lifetime costs by £4688 versus glimepiride.
In plain wordsIn a computer model, liraglutide 1.8 mg cost £4688 more over a lifetime than glimepiride.
Peptide
Liraglutide
Outcome
IncreaseLifetime cost, liraglutide 1.8 mg versus glimepiride
Study
n: not reported in source
CORE Diabetes Model
Comparator
Glimepiride
Outcome group
Cost-effectiveness · Whole body
Measurements
Incremental cost
4688 £
liraglutide 1.8 mg vs glimepiride
Source sentences
Summary
higher costs of £ 3003 ± £ 678 and £ 4688 ± £ 639 vs. glimepiride
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343806
07Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.2 mg raised lifetime costs by £1842 versus sitagliptin.
In plain wordsIn a computer model, liraglutide 1.2 mg cost £1842 more over a lifetime than sitagliptin.
Peptide
Liraglutide
Outcome
IncreaseLifetime cost, liraglutide 1.2 mg versus sitagliptin
Study
n: not reported in source
CORE Diabetes Model
Comparator
Sitagliptin
Outcome group
Cost-effectiveness · Whole body
Measurements
Incremental cost
1842 £
liraglutide 1.2 mg vs sitagliptin
Source sentences
Summary
£ 1842 ± £ 751 and £ 3224 ± £ 683 vs. sitagliptin
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343807
08Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.8 mg raised lifetime costs by £3224 versus sitagliptin.
In plain wordsIn a computer model, liraglutide 1.8 mg cost £3224 more over a lifetime than sitagliptin.
Peptide
Liraglutide
Outcome
IncreaseLifetime cost, liraglutide 1.8 mg versus sitagliptin
Study
n: not reported in source
CORE Diabetes Model
Comparator
Sitagliptin
Outcome group
Cost-effectiveness · Whole body
Measurements
Incremental cost
3224 £
liraglutide 1.8 mg vs sitagliptin
Source sentences
Summary
£ 1842 ± £ 751 and £ 3224 ± £ 683 vs. sitagliptin
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343808
09Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.2 mg was cost-effective versus glimepiride at £9449 per quality-adjusted life year gained.
In plain wordsIn a computer model, liraglutide 1.2 mg cost £9449 per quality-adjusted life year gained compared with glimepiride.
Peptide
Liraglutide
Outcome
Not applicableIncremental cost-effectiveness ratio, liraglutide 1.2 mg versus glimepiride
Study
n: not reported in source
CORE Diabetes Model
Comparator
Glimepiride
Outcome group
Cost-effectiveness · Whole body
Measurements
ICER
9449 £/QALY
liraglutide 1.2 mg vs glimepiride
Source sentences
Summary
incremental cost-effectiveness ratios of £ 9449 and £ 16,501 per quality-adjusted life year gained vs. glimepiride
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343809
10Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.8 mg was cost-effective versus glimepiride at £16,501 per quality-adjusted life year gained.
In plain wordsIn a computer model, liraglutide 1.8 mg cost £16,501 per quality-adjusted life year gained compared with glimepiride.
Peptide
Liraglutide
Outcome
Not applicableIncremental cost-effectiveness ratio, liraglutide 1.8 mg versus glimepiride
Study
n: not reported in source
CORE Diabetes Model
Comparator
Glimepiride
Outcome group
Cost-effectiveness · Whole body
Measurements
ICER
16,501 £/QALY
liraglutide 1.8 mg vs glimepiride
Source sentences
Summary
incremental cost-effectiveness ratios of £ 9449 and £ 16,501 per quality-adjusted life year gained vs. glimepiride
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343810
11Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.2 mg was cost-effective versus sitagliptin at £9851 per quality-adjusted life year gained.
In plain wordsIn a computer model, liraglutide 1.2 mg cost £9851 per quality-adjusted life year gained compared with sitagliptin.
Peptide
Liraglutide
Outcome
Not applicableIncremental cost-effectiveness ratio, liraglutide 1.2 mg versus sitagliptin
Study
n: not reported in source
CORE Diabetes Model
Comparator
Sitagliptin
Outcome group
Cost-effectiveness · Whole body
Measurements
ICER
9851 £/QALY
liraglutide 1.2 mg vs sitagliptin
Source sentences
Summary
£ 9851 and £ 10,465 per quality-adjusted life year gained vs. sitagliptin
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343811
12Computer modelNot a test of Liraglutide aloneIn silicoOther
In a model of adults with type 2 diabetes on metformin, liraglutide 1.8 mg was cost-effective versus sitagliptin at £10,465 per quality-adjusted life year gained.
In plain wordsIn a computer model, liraglutide 1.8 mg cost £10,465 per quality-adjusted life year gained compared with sitagliptin.
Peptide
Liraglutide
Outcome
Not applicableIncremental cost-effectiveness ratio, liraglutide 1.8 mg versus sitagliptin
Study
n: not reported in source
CORE Diabetes Model
Comparator
Sitagliptin
Outcome group
Cost-effectiveness · Whole body
Measurements
ICER
10,465 £/QALY
liraglutide 1.8 mg vs sitagliptin
Source sentences
Summary
£ 9851 and £ 10,465 per quality-adjusted life year gained vs. sitagliptin
1 context sentence(design, population, supporting numbers)
Summary · context
The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients' lifetimes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-2188343812

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00700817

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 665Jun 2008 to Jun 2010

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 8 Mar 2017

CompletedPhase 3Results postedNCT00318461

To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together

Novo Nordisk A/Sn = 1,091May 2006 to Nov 2008

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 7 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.